Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma.

Literature DB >> 22699774

Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma.

Kang Zhang¹, Liangfang Zhang, Robert N Weinreb.

Abstract

Blindness affects 60 million people worldwide. The leading causes of irreversible blindness include age-related macular degeneration, retinal vascular diseases and glaucoma. The unique features of the eye provide both benefits and challenges for drug discovery and delivery. During the past decade, the landscape for ocular drug therapy has substantially changed and our knowledge of the pathogenesis of ophthalmic diseases has grown considerably. Anti-angiogenic drugs have emerged as the most effective form of therapy for age-related macular degeneration and retinal vascular diseases. Lowering intraocular pressure is still the mainstay for glaucoma treatment but neuroprotective drugs represent a promising next-generation therapy. This Review discusses the current state of ocular drug therapy and highlights future therapeutic opportunities.

Entities: Disease Species

Mesh：

Substances：
Ophthalmic Solutions

Year: 2012 PMID： 22699774 DOI： 10.1038/nrd3745

Source DB: PubMed Journal: Nat Rev Drug Discov ISSN： 1474-1776 Impact factor: 84.694

195 in total

1. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7.

Authors: Veit Hornung; Margit Guenthner-Biller; Carole Bourquin; Andrea Ablasser; Martin Schlee; Satoshi Uematsu; Anne Noronha; Muthiah Manoharan; Shizuo Akira; Antonin de Fougerolles; Stefan Endres; Gunther Hartmann
Journal: Nat Med Date: 2005-02-20 Impact factor: 53.440

2. Sustained effect of travoprost on diurnal and nocturnal intraocular pressure.

Authors: Arthur J Sit; Robert N Weinreb; Jonathan G Crowston; Daniel F Kripke; John H K Liu
Journal: Am J Ophthalmol Date: 2006-06 Impact factor: 5.258

3. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study.

Authors: David M Brown; Peter A Campochiaro; Rishi P Singh; Zhengrong Li; Sarah Gray; Namrata Saroj; Amy Chen Rundle; Roman G Rubio; Wendy Yee Murahashi
Journal: Ophthalmology Date: 2010-04-09 Impact factor: 12.079

4. Complement factor H variant increases the risk of age-related macular degeneration.

Authors: Jonathan L Haines; Michael A Hauser; Silke Schmidt; William K Scott; Lana M Olson; Paul Gallins; Kylee L Spencer; Shu Ying Kwan; Maher Noureddine; John R Gilbert; Nathalie Schnetz-Boutaud; Anita Agarwal; Eric A Postel; Margaret A Pericak-Vance
Journal: Science Date: 2005-03-10 Impact factor: 47.728

5. The lipofuscin fluorophore A2E mediates blue light-induced damage to retinal pigmented epithelial cells.

Authors: J R Sparrow; K Nakanishi; C A Parish
Journal: Invest Ophthalmol Vis Sci Date: 2000-06 Impact factor: 4.799

6. Human ciliary process adrenergic receptor: pharmacological characterization.

Authors: J A Nathanson
Journal: Invest Ophthalmol Vis Sci Date: 1981-12 Impact factor: 4.799

7. Activation of the interferon system by short-interfering RNAs.

Authors: Carol A Sledz; Michelle Holko; Michael J de Veer; Robert H Silverman; Bryan R G Williams
Journal: Nat Cell Biol Date: 2003-08-24 Impact factor: 28.824

8. Development of prodrug 4-chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl benzoate (TG100801): a topically administered therapeutic candidate in clinical trials for the treatment of age-related macular degeneration.

Authors: Moorthy S S Palanki; Hideo Akiyama; Peter Campochiaro; Jianguo Cao; Chun P Chow; Luis Dellamary; John Doukas; Richard Fine; Colleen Gritzen; John D Hood; Steven Hu; Shu Kachi; Xinshan Kang; Boris Klebansky; Ahmed Kousba; Dan Lohse; Chi Ching Mak; Michael Martin; Andrew McPherson; Ved P Pathak; Joel Renick; Richard Soll; Naoyasu Umeda; Shiyin Yee; Katsutoshi Yokoi; Binqi Zeng; Hong Zhu; Glenn Noronha
Journal: J Med Chem Date: 2008-02-27 Impact factor: 7.446

9. The Alzheimer's A beta -peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration.

Authors: Lincoln V Johnson; William P Leitner; Alexander J Rivest; Michelle K Staples; Monte J Radeke; Don H Anderson
Journal: Proc Natl Acad Sci U S A Date: 2002-08-20 Impact factor: 11.205

10. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.

Authors: L P Aiello; R L Avery; P G Arrigg; B A Keyt; H D Jampel; S T Shah; L R Pasquale; H Thieme; M A Iwamoto; J E Park
Journal: N Engl J Med Date: 1994-12-01 Impact factor: 91.245

102 in total

Review 1. Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.

Authors: Rebecca K Donegan; Raquel L Lieberman
Journal: J Med Chem Date: 2015-09-25 Impact factor: 7.446

2. The In Vivo Effects of the CB₁-Positive Allosteric Modulator GAT229 on Intraocular Pressure in Ocular Normotensive and Hypertensive Mice.

Authors: Elizabeth A Cairns; Anna-Maria Szczesniak; Alex J Straiker; Pushkar M Kulkarni; Roger G Pertwee; Ganesh A Thakur; William H Baldridge; Melanie E M Kelly
Journal: J Ocul Pharmacol Ther Date: 2017-07-18 Impact factor: 2.671

Review 3. Small-interfering RNAs (siRNAs) as a promising tool for ocular therapy.

Authors: A Guzman-Aranguez; P Loma; J Pintor
Journal: Br J Pharmacol Date: 2013-10 Impact factor: 8.739

4. Coenzyme Q10 inhibits glutamate excitotoxicity and oxidative stress-mediated mitochondrial alteration in a mouse model of glaucoma.

Authors: Dongwook Lee; Myoung Sup Shim; Keun-Young Kim; You Hyun Noh; Heemin Kim; Sang Yeop Kim; Robert N Weinreb; Won-Kyu Ju
Journal: Invest Ophthalmol Vis Sci Date: 2014-02-18 Impact factor: 4.799

5. Human retinal progenitor cell transplantation preserves vision.

Authors: Jing Luo; Petr Baranov; Sherrina Patel; Hong Ouyang; John Quach; Frances Wu; Austin Qiu; Hongrong Luo; Caroline Hicks; Jing Zeng; Jing Zhu; Jessica Lu; Nicole Sfeir; Cindy Wen; Meixia Zhang; Victoria Reade; Sara Patel; John Sinden; Xiaodong Sun; Peter Shaw; Michael Young; Kang Zhang
Journal: J Biol Chem Date: 2014-01-09 Impact factor: 5.157

6. Constructing a statistical atlas of the radii of the optic nerve and cerebrospinal fluid sheath in young healthy adults.

Authors: Robert L Harrigan; Andrew J Plassard; Louise A Mawn; Robert L Galloway; Seth A Smith; Bennett A Landman
Journal: Proc SPIE Int Soc Opt Eng Date: 2015-03-20

10. Human Pluripotent Stem Cell-Derived Retinal Ganglion Cells: Applications for the Study and Treatment of Optic Neuropathies.

Authors: Jessica A Cooke; Jason S Meyer
Journal: Curr Ophthalmol Rep Date: 2015-08-07